Na Cocer Peptides bin rayt am 
13 dez bifo
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Fɔ fat pasmak de bi wan siriɔs tin we de apin ɔlsay na di wɔl, i nɔ jɔs de afɛkt di bɔdi wɛlbɔdi bɔt i gɛt fɔ du wit sik dɛn we nɔ de mɛn lɛk di sik dɛn we de ambɔg di at ɛn di blɔd ɛn tayp 2 dayabitis. Fɔ fɛn sef ɛn fayn we fɔ lɛf fɔ it bɔku bɔku it dɔn bi wan impɔtant tin we dɛn dɔn du fɔ du risach pan mɛrɛsin. Tizepatide na wan drɔg we de wok pan tu riseptɔ, we de gi nyu we fɔ trit pɔsin we fat pasmak.
Figure 1: Struktכr εn initial stεp dεm fכ mכlikul signal tru GIPR εn GLP1R in GIPR–GLP1R dual agonist RG7697–NNCOO90-2746 εn LY3298176.
Tizepatide in Dual Risεptor Agonist Mεkanism
(1) GIP Risεptor Agonist Mεkanism
Fisiolojikal Besis fɔ di GIP Risɛptɔ
di GIP rεsεpכta na spεshal sεl rεsεpכta we de insay plεnti כgan dεm, we inklud di pankrias, adipos tisu, liva, εn mכsul dεm. pan di sכfayz pan di pankrεas aylet β sεl dεm, we di GIP כmon de biεn dis rεsεpכta, i de aktibכt intasεlulyar signal path dεm, we de mek di intasεlulyar cAMP lεvεl dεm inkrεs. afta dat cAMP de aktibכt protin kinaz A, we, tru wan siriכs riakshכn, de protεkt insulin sekreshכn.
insay adipos tisu, aktibכshכn fכ di GIP rεsεpכta de rεgεl di adiposyt mεtabolism. i de mek di adiposyt dεm tek glukכs, i de inkrεs fεt asid sεntez εn stכrej, εn i de inhibit lipolysis. rεsכch sho se dis prכsεs kin kכnεkt wit inkrεs pan di nכmba fכ glukכs transpכrta dεm (GLUT4), we de mek i izi fכ glukכs kכmכt insay adiposyt dεm, we de gi raw mεtirial fכ fεt sεntez.
Di Efεkt dεm we Tizepatide Gεt pan di GIP Risεptor
Tizepatide gεt strכkchכ we lεk di GIP כmon εn i kin spεshal biεn εn aktibכt GIP rεsεpכta dεm. we yu kכmpεr wit εndojεnik GIP, Tizepatide gεt strכng binding afiniti fכ rεsεpכta dεm, we de mek i ebul fכ aktibכt mכr ifektiv aktibכshכn fכ signal path dεm. rεsכch dεn sho se afta i biεn to rεsεpכta dεm, i kin sכstaynεbli inkrεs di cAMP lεvεl dεm, we de mek i mכr sכmtεm protεkt insulin sekreshכn. insay adipos tisu, in prεsis rεgulεshכn fכ lipid mεtabolism afta rεsεpכta aktibכshכn de mek כl tu di glukכs כptek bay adiposyt dεm εn bεlε sεntesis εn stכrej fεt asid dεm, we de mek fεt akyumyuleshכn pasmak—na imכtant tin fכ mεnten nכmal lipid mεtabolism.
Fig 2: Kכmparativ ifekt dεm fכ RG7697/NNCOO90-2746 εn LY3298176 frכm klinik trial, εksεpt usay asterisk dεm sho (dεn sho am כnli insay rodεnt dεm).
(2) GLP-1 Risεptor Aktivεshכn Mεkanism
Fisiolojikal Bεsis כf GLP-1 Risεptor dεm
di GLP-1 rεsεpכta na sεl rεsεpכta bak we dεn de sheb fכs insay pankrεas β sεl dεm, di gεstrointestinal trakt, εn di bren. insay pankrεas β sεl dεm, GLP-1 de biεn di rεsεpכta εn i de aktibכt signal path dεm fכ protεkt insulin sekreshכn. difrεnt frכm GIP, di ifekt dεm we GLP-1 gεt de rεgεl bay di blכd glukכs lεvεl: i de mek insulin sekreshכn we di blכd glukכs hכy εn in ifekt dεm de wik we di blכd glukכs nכmal, we de mek i sef.
insay di gεstrointestinal trakt, di aktibכshכn fכ di GLP-1 rεsεpכta de mek di it rεtεnshכn na di bεlε lכng, we de mek di bכdi glukכs spik kwik kwik wan afta it, εn i de inhεbit di gεstrik asid sekreshכn bak, we de protεkt di gεstrointestinal mכkus. insay di bren, i de wok pan rijyכn dεm we de kכntrכl di apεtit, i de rεdכks angri εn i de mek i satis bכku, we de mek i rεdכks fכ it.
Tizepatide in ifekt dεm pan di GLP-1 rεsεptכr
Tizepatide gεt strכng binding afiniti fכ GLP-1 rεsεpכta dεm, εn we i aktibכt, i de prodyuz ifekt dεm we sכm kayn we lεk di εndojεnik GLP-1. we i kam pan di blכd glukכs rεgulεshכn, i de mek insulin sekreshכn bays pan di blכd glukכs lεvεl, we de mek i bεtε kכntrכl di blכd glukכs. insay di gεstrointestinal trakt, di ifekt we i de du fכ delay di gastric εmpti de sho mכr pas di wan we sכm tradishכnal drog dεm de gi. Insay di bren, di tin we i de du we de mek pɔsin nɔ want fɔ it kin kɔntinyu fɔ de, ɛn i kin ɛp fɔ lɛ pɔsin nɔ gɛt bɔku bɔku bɔdi.
(3) Sinerjistik Efεkt dεm fכ Dual Risεptor Agonism
Sinerjistik Efεkt dεm na Blɔd Glukɔs Rεgulεshɔn
Tizepatide de akt pan כl tu di GIP εn GLP-1 rεsεpכta dεm, we de rεsult in bεtε blכd glukכs rεguleshכn. GIP fכs de protεkt insulin sekreshכn kwik kwik wan insay di εli postprandial pεriכd, we de ridyus di bכdi glukכs pik; GLP-1 de kכntinyu fכ akt כlsay di prכsεs afta di it, nכto nכmכ de mek insulin sekreshכn bכt i de delay di gεstrik εmpti, rεdכks fכ it, εn mεnten di blכd glukכs lεvεl stebul. fכ aktibכt di tu rεsεpכta dεm wan tεm de rεsult in mכr optimal postprandial bכdi glukכs kכntrכl. Fɔ ɛgzampul, insay dayabitik animal ɛkspiriɛns, Tizepatide bin ridyus di blɔd glukɔs we de go ɔp afta it pas ɛni wan pan di GIP ɔ GLP-1 drɔgs dɛn nɔmɔ, ɛn di blɔd glukɔs bin kam bak to nɔmal kwik kwik wan.
Sinerjistik Efεkt pan Enεji Mεtabolism
we i kam pan enεji mεtabolism, di GIP rεsεpכta agonist dεm de mek di fεt sεl dεm tek glukכs, bכt כnda di inflכεns fכ Tizepatide, fεt sεntesis nכ de akumulet pasmak. pan tap dat, di GLP-1 rεsεpכta agonist dεm de sכpres di apεtit, inkrεs di satiety, ridyus di kalori intake, εn promuot fεt bכn εn εnεji spεnd. Dis dual akshכn de bεlεns di enεji intake εn εspεndishכn. Fɔ ɛgzampul, insay ɔbisiti animal ɛkspiriɛns, afta dɛn yuz Tizepatide fɔ sɔm tɛm, di animal dɛn bɔdi wet bin go dɔŋ, bɔdi fat bin ridyus, ɛn di basal mɛtabolism bin aksɛleret.
Figure 3: difrεns bitwin sinagεstik agonist dεm (chimeras) εn pεptida fכs strכkchכ dεm
Aplikeshɔn fɔ Tizepatide insay Ɔbisiti Tritmɛnt
(1) Ifɛkt dɛn we pɔsin kin du we i nɔ gɛt bɔku bɔku bɔdi
Prɛklinik Risach Evidɛns
Insay animal ɛkspiriɛns, fat mays dɛn we dɛn gi Tizepatide sho se dɛn de lɔs dɛn wet smɔl smɔl ova tɛm, wit mɔ pronɔns ridyushɔn kɔmpia to di kɔntrol grup. di analisis fכ di bכdi fεt sho se i nכ כnli ridyus di fεt mas bכt i de impruv di fεt distribushכn, we de ridyus di vishכnal fεt akyumyuleshכn. di praymar mεkanism dεm na tu fכs: fכs, di aktibכshכn fכ di GLP-1 rεsεpכta de sכpres di apεtit bay we i de inhεbit di bren in angri sεntr; sεkכn, i de mek fεt bכn εn i de mek di εnεji we i de spɛn bכku.
Klinik trial pruf
Insay klinik trayal dɛn we dɛn bin de tɔch pipul dɛn we fat, Tizepatide bin sho bak se i gɛt gud we fɔ lɔs dɛn wet. Multiple randomized controlled trials sho se afta wan tɛm we dɛn dɔn trit, di pasɛnt dɛn bɔdi wet bin go dɔŋ bad bad wan. Fɔ ɛgzampul, insay wan 24 wik trayal, di tritmɛnt grup bin gɛt avrej wet lɔs we na lɛk 10%, we di plesibo grup sho smɔl chenj. Apat frɔm dat, di say we di sikman dɛn wes de ɛn di say we dɛn de hip bak bin go dɔŋ, we sho se i nɔ jɔs de mek dɛn lɔs dɛn wet bɔt i de mek di fat we dɛn de sheb fayn ɛn i de mek dɛn nɔ gɛt sik dɛn we dɛn kin gɛt we dɛn fat pasmak.
(2) Improvεmεnt כf Mεtabolik Sεndrכm-Rεlatεd Indikεtכr dεm
Impruv di Blɔd Glukɔs Rigyuleshɔn
Bɔku tɛm, di wan dɛn we fat kin gɛt prɔblɛm wit dɛn blɔd glukɔs, ɛn Tizepatide kin mek dɛn kɔntrol di glukɔs na dɛn blɔd fayn fayn wan ɛn i kin mek dɛn lɔs dɛn wet. Insay klinik trial, di pasɛnt dɛn bin si se di blɔd glukɔs we dɛn bin de fast, di blɔd glukɔs we dɛn bin de it afta dɛn it, ɛn di ɛmoglobin A1c (we na wan lɔng tɛm blɔd glukɔs kɔntrol indikɛtɔ) bin ridyus afta dɛn dɔn trit dɛn. dis na biכs i de akt tru tu rεsεpכta mεkanism dεm, we de protεkt insulin sekreshכn εn εnhans insulin sεnsitiviti, we i de delay di gεstrik εmpti εn ridyus di fכd absכpshכn kwik kwik wan. We yu kɔmpia am wit tradishɔnal mɛrɛsin dɛn we de mek pɔsin nɔ gɛt dayabitis, i nɔ jɔs de mek di glukɔs na di blɔd go dɔŋ bɔt i de mek dɛn nɔ gɛt bɔku bɔku bɔdi, ɛn dis de gi mɔ bɛnifit to di wan dɛn we fat we gɛt dayabitis.
Lipid Rɛgyuleshɔn Impruvmɛnt
Bɔku tɛm, we pɔsin fat kin kam wit dislipidemia, lɛk we di triglisɛrɛyd dɛn kin bɔku ɛn di ay-dɛnsity lipoprotein (HDL) lɛvɛl we smɔl. Tizepatide kin rεgεl di lipid dεm: afta dεn gi am, di sik pipul dεm kin εkspiriεns rεdכks triglisεrayd lεvεl εn inkrεs HDL lεvεl. dis kin riliyt to in rεgulεshכn fכ lipid mεtabolism, lεk fכ mek di fεt sεl dεm tek glukכs, fכ ridyus fεt asid we de rilis, εn fכ εnhans fεt כksidεshכn, we de mek di lipid profayl dεm impruv εn lכs di risk fכ di kכdivaskyul sik.
(3) Pɔtɛnɛshɛl bɛnifit fɔ di kadiovaskular sistɛm
Blɔd prɛshɔn rigyuleshɔn
Fɔ fat na wan pan di tin dɛn we kin mek pɔsin gɛt ay blɔd prɛshɔn. Klinik stɔdi dɔn sho se afta dɛn dɔn trit di sikman dɛn wit Tizepatide, di sikman dɛn sistolik ɛn dayastolik blɔd prɛshɔn ɔl tu kin go dɔŋ. Dis kin gɛt fɔ du wit di wet we pɔsin de lɔs ɛn we i de mek di mɛtabolism bɛtɛ: we i de lɔs di wet i de ridyus di lod we de pan di at, ɛn we di glukɔs ɛn lipid we de na di blɔd bɛtɛ de ɛp fɔ mek di vaskul dɛn gɛt wɛlbɔdi bak ɛn fɔ mek di vaskul dɛn nɔ de wok fayn. apat frכm dat, di ifekt dεm we i de du pan di gεstrointestinal trakt kin indyεkt infכmeshכn di nyuroεndokrin rεguleshכn, we de rεgεl di bכdi prεshכn.
Vaskulεr prכtektiv ifekt dεm
krכnik inflameshn εn כksidεtiv strεs na kכmכn pan di wan dεm we fat, we kin pwεl di vaskulεr εndoteyl εn protεkt atεrosklεrosis. Tizepatide de protεkt di vaskulεr εndoteyl bay we i de impruv mεtabolism, ridyus di rilis fכ inflammatory fכktכ dεm, εn lכs כksidεtiv strεs. stכdi dεm sho se afta tritmεnt, di sikman dεm inflammatory mak dεm lεk C-reactive protein (CRP) dεn dכn dכn, εn vaskulεr εndoteyl fכnshכn indikεtכ dεm lεk nitric oxide rilis de inkrεs, we sho se di vaskulεr hεlth bεtεh εn i de εp fכ prεvεnshכn kכdivaskyul sik dεm.
Dɔn
Tizepatide de sho signifyant pכtεnshal in obesity tritmεnt bay we i de akt wan tεm pan GIP εn GLP-1 rεsεpכta dεm. i nכ de כnli fכ mek yu lכs di wet bכt i de mek di mεtabolik indikεt dεm lεk di glukכs na di bכdi εn di lipid lεvεl dεm, pan כl we i de gi di kכdivaskyul protεkshכn. Tru in multifaceted mechanisms of action, e de gi nyu tritmɛnt opshɔn fɔ fat ɛn di kɔndishɔn dɛn we gɛt fɔ du wit am.
Sos dɛn we dɛn pul
[1] Boer GA, Hay DL, Tups A. Obesiti fכmכtεrapi: inkrεtin akshכn na di sεntri nεv sεstem[J]. Trends in Famakolojik Sayns, 2023,44(1):50-63.DOI:10.1016/j.tips.2022.11.001.
[2] Jensen T. L., Nden A. B. O., Karstoft K., ɛn ɔda pipul dɛn. Tirzepatid we gɛt di sik. Dual GLP-1/GIP rεsεptכr agonist, Tritmεnt fכ tayp 2 dayabεtis εn כbisiti[J]. Drugs of di Fyuchɔ, 2023. DOI: 10.3389/fendo.2022.1004044
[3] Wilard F. S., Douros J. D., Geb M. B., ɛn ɔda pipul dɛn. Tirzepatid na imbalans εn bias dual GIP εn GLP-1 rεsεptכr agonist[J]. Jci Insight, 2020,5(17).DOI: 10.1172/jci.insayt.140532. Di wan dɛn we de stɔdi di Baybul.
[4] Bastin M, Andreelli F. Dual GIP-GLP1-Rεsεptor Agonists In Di Tritmεnt כf Tayp 2 Dayabitis: Wan Sכt Rivyu Pan Emerging Data εn Tεrapi Pכtεnshal[J]. Dayabitis Mεtabolik Sεndrכm εn Obisiti-Tכgεt εn Tεrapi, 2019,12:1973-1985.DOI:10.2147/DMSO.S191438.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
